Mallinckrodt (NYSE:MNK) had its price objective reduced by Mizuho from $25.00 to $22.00 in a report issued on Thursday morning, The Fly reports. They currently have a neutral rating on the stock.

A number of other brokerages have also weighed in on MNK. ValuEngine lowered shares of Mallinckrodt from a sell rating to a strong sell rating in a report on Monday, May 13th. SunTrust Banks set a $20.00 price objective on shares of Mallinckrodt and gave the company a hold rating in a report on Tuesday, May 14th. Morgan Stanley set a $32.00 price objective on shares of Mallinckrodt and gave the company a hold rating in a report on Thursday, February 28th. Finally, Canaccord Genuity set a $40.00 price objective on shares of Mallinckrodt and gave the company a buy rating in a report on Monday, March 18th. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Mallinckrodt currently has an average rating of Hold and an average price target of $30.44.

NYSE MNK opened at $14.68 on Thursday. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.08 and a current ratio of 1.45. Mallinckrodt has a 12-month low of $13.45 and a 12-month high of $36.65. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of 1.83, a PEG ratio of 0.15 and a beta of 2.12.

Mallinckrodt (NYSE:MNK) last released its quarterly earnings results on Tuesday, May 7th. The company reported $1.94 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.73 by $0.21. Mallinckrodt had a negative net margin of 118.53% and a positive return on equity of 14.22%. The business had revenue of $791.00 million for the quarter, compared to analyst estimates of $766.27 million. During the same period in the previous year, the company earned $1.31 earnings per share. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. Sell-side analysts anticipate that Mallinckrodt will post 8.38 EPS for the current year.

Large investors have recently bought and sold shares of the business. CWM LLC boosted its holdings in Mallinckrodt by 222.8% in the first quarter. CWM LLC now owns 1,159 shares of the company’s stock valued at $25,000 after purchasing an additional 800 shares during the last quarter. FNY Investment Advisers LLC boosted its holdings in Mallinckrodt by 210.4% in the fourth quarter. FNY Investment Advisers LLC now owns 2,288 shares of the company’s stock valued at $36,000 after purchasing an additional 1,551 shares during the last quarter. We Are One Seven LLC purchased a new stake in Mallinckrodt in the fourth quarter valued at $38,000. QS Investors LLC boosted its holdings in Mallinckrodt by 14.3% in the fourth quarter. QS Investors LLC now owns 4,000 shares of the company’s stock valued at $64,000 after purchasing an additional 500 shares during the last quarter. Finally, Quantamental Technologies LLC purchased a new stake in Mallinckrodt in the fourth quarter valued at $80,000.

Mallinckrodt Company Profile

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.

See Also: What are economic reports?

The Fly

Analyst Recommendations for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.